Efficacy of Spironolactone Combined With Antihypertensive Drugs in Patients With Primary Aldosteronism

The goal of this observational study is to learn about the optimal dose of spironolactone treatment and the long-term outcomes on cardiovascular and cerebrovascular events in patients with lateralized PA who are unwilling to undergo surgery. The main question it aims to answer is: 1. What is the long-term effect of spironolactone treatment for lateralized PA? 2. What is the optimal dose of spironolactone treatment for the relief of renin inhibition in patients with lateralized PA? Participants will receive spironolactone treatment as part of their regular medical care for more than 12 months, and their clinical indicators, including blood pressure, biochemical remission, cardiovascular and renal damage, and the incidence of cardiovascular and cerebrovascular events, will be analyzed.

NCT Number	NCT07137364
Lead Sponsor	Third Military Medical University
Conditions	Primary Aldosteronism, Hypertension
Enrollment	350 participants
Start Date	2022-05-01
Primary Completion	2025-12-01 (estimated)
Study Completion	2026-04-30 (estimated)
Updated on ClinicalTrials.gov	2025-08-22